Abstract
Objectives. The study aims to define the economic resources needed to manage chronic
rhinosinusitis with nasal polyposis (CRSwNP), assuming the hospital perspective, based on
different patient characteristics, within a 24-month time horizon.
Methods. Real-world data were collected in 3 Italian hospitals. A time-driven activity-based costing approach was implemented to map and assess the pathways for CRSwNP. The following drivers were considered: diagnostic services, drugs, consumables, human resources, equipment and overhead costs based on the length of stay. Costs related to management of comorbidities and adverse events were evaluated. Three main groups of patients were identified: ineligible for surgery; having 1 intervention; having more than 1 intervention. The economic absorption of patients who continued corticosteroid treatment was analysed.
Results. Patients experiencing 1 intervention had a cost of 3,453.31 € that increased to
4,705.03 € for those who required additional surgery. The cost of intranasal corticosteroids
was 649.20 €, whereas the cost of oral corticosteroids was 37.60 € per patient.
Conclusions. The results demonstrate the strategic relevance of analytical cost definitions
of the clinical pathway for CRSwNP, which can help to support decision makers in the review of internal procedures and in the definition of proper reimbursement tariffs.